Italia markets close in 2 hours 12 minutes

Ligand Pharmaceuticals Incorporated (LGND)

NasdaqGM - NasdaqGM Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
72,52-6,35 (-8,05%)
Alla chiusura: 04:00PM EDT
71,57 -0,95 (-1,31%)
Dopo ore: 07:12PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente78,87
Aperto78,70
Denaro72,26 x 100
Lettera72,65 x 100
Min-Max giorno72,50 - 78,70
Intervallo di 52 settimane49,24 - 94,57
Volume130.939
Media Volume169.445
Capitalizzazione1,284B
Beta (5 anni mensile)0,92
Rapporto PE (ttm)23,93
EPS (ttm)3,03
Prossima data utili02 mag 2024 - 06 mag 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendo02 lug 2010
Stima target 1A116,80
  • GlobeNewswire

    Sermonix Pharmaceuticals Shares Results of EQUALS 2 Survey on Vaginal and Sexual Health in Patients with ER+/HER2- Metastatic Breast Cancer

    More than 60% of survey respondents experienced vaginal symptoms and felt their sexual health was negatively impacted by prior endocrine therapyAbout half never or almost never felt sexual desire or interest in the previous month, particularly those whose sexual health was negatively impacted by prior endocrine therapy (61%)Findings were presented in a poster at The Menopause Society 2023 Annual Meeting COLUMBUS, Ohio, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately

  • GlobeNewswire

    Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 Protection

    – The Company and Ligand Pharmaceuticals sign agreement to sell substantially all of Novan’s assets under Section 363 of the U.S. Bankruptcy Code, along with a commitment from Ligand to fund $15 million in debtor-in-possession financing – – Progression toward PDUFA goal date of January 5, 2024, for berdazimer gel, 10.3% (SB206) continues, with Pre-Approval Inspection (PAI) complete and favorable mid-cycle review communication from FDA – – Agreement provides a path forward for a product, if appro

  • GlobeNewswire

    Sermonix Pharmaceuticals to Present Two Posters at The Menopause Society 2023 Annual Meeting

    One poster examines baseline vaginal and vulvar symptoms in ESR1-mutated, ER+/HER2- metastatic breast cancerSecond poster shares survey results examining vaginal and sexual health in ER+/HER2- metastatic breast cancer patients COLUMBUS, Ohio, June 29, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers harboring ESR1 mutations, today announced it will present two post